This was the second of a two part investigation looking at concerns about a pivotal trial for the anti-clotting drug, rivaroxaban. In this investigation, Deborah found that companies were aware of concerns about a faulty device in a regulatory trial

https://www.bmj.com/content/354/bmj.i5131

Write A Comment